Imagine you are in early stages of the development of a new small molecule for the treatment of a disease. Imagine that this disease is already being treated with a standard-of-care (SoC) treatment. You are sure that your new molecule is more effective than the SoC treatment and, in addition, could be useful for more indications, including disease-related symptoms. But, how to check it using a human-based model? How to demonstrate to investors that it is worthy to continue with the development of the compound?
In vitro or animal testing are the most common ways to test the efficacy of an experimental compound. However, these methods have limitations as they only partially represent clinical responses in humans. Cell lines do not represent the whole complexity of human beings, as they are simplified models of human physiology, and animal physiology is often not a trustworthy model of the human molecular performance. In addition, these kinds of in vitro and in vivo assays are time-consuming and expensive.
In Anaxomics we propose a new way to analyse the clinical efficacy of experimental compounds at early stages of development, overcoming some of these limitations. Employing our TPMS technology it is possible to assess the efficacy of either an experimental or an already marketed compound by just knowing its targets. Through artificial neural networks (ANNs), a type of Artificial Intelligence methods, we are able to predict the efficacy of a drug in treating a disease by analysing the effect of the modulation of its molecular targets over a molecularly defined model of the disease.
But, which advantages do Anaxomics models provide compared to lab testing? In the first place, Anaxomics computational models contain all the known information about human physiology and pathology; thus, we are able to reliably reproduce the whole complexity of human responses and predict clinical outcomes impossible to reproduce in some lab models. Another advantage of our method is that it allows to test multiple drugs within a same model, providing an easy way to compare efficacies, including the assessment of potential synergism of combination therapies, just by comparing single predictive values. In addition to the assessment and comparison of the efficacy of different drugs in the treatment of a single pathology, our models also allow to easily test the efficacy of your compound of interest for other indications in a high-throughput mode, in contrast to lab models, which are disease-specific. And all we need in order to perform this in silico analysis is knowing the molecular targets of the compounds (but, if you don’t know them, don’t worry! We can predict the target profile of a drug based on their structure and biological and clinical features).
By using this technology, we offer companies the possibility to perform a drug market analysis including efficacy information, in order to highlight the strengths of new compounds compared to other competitors in development or already in the market, all from a human physiology-based point of view. This service can also be useful for investors that are in due diligence processes; as we can help them find the best investment option. The following figure summarizes the whole process:
We will explain our services for investors in an upcoming entry. As always, meanwhile we invite you to get in contact with us in order to solve any doubt or treat any topic of your interest.
Latest posts by Mireia Coma (see all)
- The SysMalVac Research Project: Systems Biology for developing companion biomarkers of an effective malaria vaccine - February 11, 2015
- Systems Biology for Cosmetics and Nutraceuticals (6) – Development of a new nutraceutical to prevent a pathology - January 12, 2015
- Systems Biology for Cosmetics and Nutraceuticals (6) – Biomolecular study of food components - November 10, 2014